Instil Bio, Inc. (TIL) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US45783C2008
Price
6.83 USD
Market cap
45.51 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–
Instil Bio, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -78.58 m USD |
| EBIT | -65.54 m USD |
| Net income | -71.37 m USD |
| Diluted EPS – continuing operations | -10.70 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Instil Bio, Inc.
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
More stocks
- Roscan Gold Corp (ROS.V)
- Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares (AZI)
- Edge Copper Corporation (EDCU.TO)
- LiveOne, Inc. (LVO)
- Sun Max Tech Ltd (6591.TW)
- Massimo Group (MAMO)
- FUEL TECH, INC. (FTEK)
- PDS Biotechnology Corp (PDSB)
- Brand X Co. Ltd. (337930.KQ)
- Kaonmedia Co Ltd (078890.KQ)
- Electra Battery Materials Corp (ELBM.V)
- TaiRx, Inc. (6580.TWO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.